Mapping retinal fluorescein leakage with confocal scanning laser fluorometry of the human vitreous.

Mapping retinal fluorescein leakage with confocal scanning laser fluorometry of the human vitreous.

Mapping retinal fluorescein leakage with confocal scanning laser fluorometry of the human vitreous.

Lobo C., Bernardes R., Santos F., Cunha-Vaz J.

Objective: To demonstrate an objective, quantitative, and sensitive method of mapping retinal fluorescein leakage into the vitreous while simultaneously imaging the retina.

Methods: A prototype Zeiss confocal scanning laser ophthalmoscope was modified to obtain fluorometric measurements from 18 optical planes across the retina and cortical vitreous, separated from each other by 150 µm, and parallel to the retinal surface. After intravenous administration of fluorescein, an axial graphic of equivalent fluorescein concentration in the vitreous may be obtained from any region of interest. After correcting for fluorescence levels in the retina and choroid and plasma levels of free fluorescein, permeability values of the blood-retinal barrier to fluorescein were obtained from 1512 regions measuring 75 x 75 µm, from a total 3150 x 2700-µm area of the fundus, generating a detailed map of retinal fluorescein leakage. The method was assessed in vitro and in 7 healthy subjects who underwent scans during separate visits. Depth resolution and influence of chorioretinal fluorescence were further tested in 2 patients with multiple drusen and in 2 eyes after vitrectomy. Fourteen eyes from 7 patients with diabetes and nonproliferative retinopathy were also examined. Lateral resolution was tested in 3 diabetic eyes that underwent focal photocoagulation. Four eyes from 2 patients with diabetes and minimal retinopathy were examined at 3-month intervals. All eyes examined had less than 2 diopters of astigmatism.

Results: Characteristics of the modified confocal scanning laser fluorometer included a lower limit of detection equal to 0.40 Eq ng/mL and depth precision of ±15 µm. Values for the blood-retinal barrier permeability index in healthy subjects, measured 30 minutes after a single intravenous pulse of fluorescein (14 mg/kg), ranged from 1.3 ± 0.4 x 10-6 cm/s over the foveal avascular zone to 2.2 ± 0.6 x 10-6 cm/s over vessels in the retina. Diabetic eyes with retinopathy showed higher values, ranging from 1.4 to 15.0 x 10-6 cm/s. Vitrectomized eyes and eyes with multiple drusen showed the validity of the correction algorithm demonstrating that measurements of fluorescence in the vitreous are not influenced by the chorioretinal fluorescence level. Argon laser photocoagulation burns placed in the diabetic retina demonstrated a lateral resolution on the order of 75 to 100 µm. Intravisit and intervisit reproducibility was ±10.2% and ±13%, respectively.

Conclusions: This new method measures localized alterations of the blood-retinal barrier and allows for direct correlation with retinal anatomy. Its most interesting feature is the ability to map retinal fluorescein leakage while simultaneously imaging the retina. This capability is expected to improve our understanding and management of retinal disease.

Arch. Ophthalmol. 1999; 117: 631-637.

1999
http://archopht.ama-assn.org/cgi/content/abstract/117/5/631

Novel imaging techniques for diabetic macular edema.

Novel imaging techniques for diabetic macular edema.

Novel imaging techniques for diabetic macular edema.

Lobo C., Bernardes R., Faria de Abreu J., Cunha-Vaz J.

Retinal edema should be defined as any increase of water of the retinal tissue resulting in an increase in its volume. It may be of cytotoxic or vasogenic origin. Development of vasogenic macular edema is dependent on a series of factors such as blood pressure, blood-retinal barrier permeability, retinal cell damage, retinal tissue osmotic pressure and retinal tissue compliance. Objective measurements of retinal thickness are now possible using the Retinal Thickness Analyser. Localised measurements of blood-retinal barrier permeability may also be obtained using the Retinal Leakage Analyser, a modified confocal scanning laser fluorometer, while obtaining simultaneously angiographic images of the choroid and retina. These new imaging techniques show that cytotoxic and vasogenic retinal edema may occur independently in the early stages of diabetic retinopathy. These findings offer new perpectives for designing novel therapeutic strategies.

Doc. Ophthalmol. 1999, 97: 341-347.

1999
http://www.springerlink.com/content/j312550q01605608/

Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes. A seven-year prospective follow-up study.

Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes. A seven-year prospective follow-up study.

Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes. A seven-year prospective follow-up study.

Cunha-Vaz JG, Lobo C, Castro Sousa JP, Leite E, Faria de Abreu JR

Graefe?s Arch. Clin. Exp. Ophthalmol. 1998; 236: 264-268.

1998

Contrast sensitivity after implantation of diffractive bifocal and monofocal intraocular lens.

Contrast sensitivity after implantation of diffractive bifocal and monofocal intraocular lens.

Contrast sensitivity after implantation of diffractive bifocal and monofocal intraocular lens.

Haaskjold E, Allen D, Burton R, Webber S, Sandvig K, Jyrkkio H, Leite E, Liekfeld A, Philipson B, Nystrom A, Wollensak J

J. Cataract. Refract. Surg. 1998; 24: 653-658.

1998

Interferon alfa-2 is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomised placebo ? controlled clinical trial.

Interferon alfa-2 is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomised placebo ? controlled clinical trial.

Interferon alfa-2 is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomised placebo ? controlled clinical trial.

Cunha-Vaz JG, Faria de Abreu JR, Silva R

Pharmacological Therapy for Macular Degeneration Study Group. Arch. Ophthalmol. 1997; 865-872.

1997

Permeability of the blood-retinal barrier in healthy humans. European Concerted Action on Ocular Fluorometry.

Permeability of the blood-retinal barrier in healthy humans. European Concerted Action on Ocular Fluorometry.

Permeability of the blood-retinal barrier in healthy humans. European Concerted Action on Ocular Fluorometry.

Van Schaik KJ, Heinz B, Larsen M, Leite E, Rosas V, Schalnus, Van Best JÁ

Graefe?s Arch. Clin. Exp. Ophthalmol. 1997; 235: 639-646.

1997